Empagliflozin's Cardiorenal Benefits Appear to Persist.

IF 63.1 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Jama-Journal of the American Medical Association Pub Date : 2024-11-22 DOI:10.1001/jama.2024.23620

Samantha Anderer

引用次数: 0

查看原文本刊更多论文

Empagliflozin 对心衰的益处似乎持续存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jama-Journal of the American Medical Association 医学-医学：内科

CiteScore

48.20

自引率

0.90%

发文量

1569

审稿时长

2 months

期刊介绍： JAMA (Journal of the American Medical Association) is an international peer-reviewed general medical journal. It has been published continuously since 1883. JAMA is a member of the JAMA Network, which is a consortium of peer-reviewed general medical and specialty publications.